Equity price surges following an official U.S. Food and Drug Administration drug approval vary dramatically based on the commercial market potential of the therapeutic asset, the size of the issuing company, and prevailing market conditions. While large pharmaceutical corporations might experience modest, steady gains, small-cap and micro-cap biotechnology firms can witness explosive percentage spikes of fifty, one hundred, or even several hundred percent overnight. However, these initial rallies can sometimes retrace if commercial execution falters or if secondary equity offerings are quickly launched to fund subsequent manufacturing and distribution overhead.